Search Results - "Varunok, Peter"

S1229 Single Use Duodenoscopes Are Financially Viable for ERCP: A Real-World Study Within a Community Setting by Dean, Robert, Salvatore, Buffa, Varunok, Peter, Ashraf, Khuram

Get full text

All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study by Nelson, David R., Cooper, James N., Lalezari, Jacob P., Lawitz, Eric, Pockros, Paul J., Gitlin, Norman, Freilich, Bradley F., Younes, Ziad H., Harlan, William, Ghalib, Reem, Oguchi, Godson, Thuluvath, Paul J., Ortiz‐Lasanta, Grisell, Rabinovitz, Mordechai, Bernstein, David, Bennett, Michael, Hawkins, Trevor, Ravendhran, Natarajan, Sheikh, Aasim M., Varunok, Peter, Kowdley, Kris V., Hennicken, Delphine, McPhee, Fiona, Rana, Khurram, Hughes, Eric A.

“…Treatment options for patients with hepatitis C virus (HCV) genotype 3 infection are limited, with the currently approved all‐oral regimens requiring 24‐week…”
Get full text

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin by Zeuzem, Stefan, Jacobson, Ira M, Baykal, Tolga, Marinho, Rui T, Poordad, Fred, Bourlière, Marc, Sulkowski, Mark S, Wedemeyer, Heiner, Tam, Edward, Desmond, Paul, Jensen, Donald M, Di Bisceglie, Adrian M, Varunok, Peter, Hassanein, Tarek, Xiong, Junyuan, Pilot-Matias, Tami, DaSilva-Tillmann, Barbara, Larsen, Lois, Podsadecki, Thomas, Bernstein, Barry

“…In this trial in patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon and ribavirin, retreatment with…”
Get full text

Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine by Lalezari, Jacob, Sullivan, J. Greg, Varunok, Peter, Galen, Edward, Kowdley, Kris V, Rustgi, Vinod, Aguilar, Humberto, Felizarta, Franco, McGovern, Barbara, King, Martin, Polepally, Akshanth R, Cohen, Daniel E

“…Background & Aims Hepatitis C virus (HCV)-infected patients with a history of injection drug use have low rates of initiation and completion of…”
Get full text

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis by Lawitz, Eric, Makara, Mihály, Akarca, Ulus Salih, Thuluvath, Paul J, Preotescu, Liliana Lucia, Varunok, Peter, Morillas, Rosa Mª, Hall, Coleen, Mobashery, Niloufar, Redman, Rebecca, Pilot-Matias, Tami, Vilchez, Regis A, Hézode, Christophe

“…Background & Aims Interferon-free treatment options are rapidly evolving for patients with chronic hepatitis C virus (HCV) genotype 1b (GT1b) infection with…”
Get full text

Peginterferon alfa‐2b and weight‐based or flat‐dose ribavirin in chronic hepatitis C patients: A randomized trial by Jacobson, Ira M., Brown, Robert S., Freilich, Bradley, Afdhal, Nezam, Kwo, Paul Y., Santoro, John, Becker, Scott, Wakil, Adil E., Pound, David, Godofsky, Eliot, Strauss, Robert, Bernstein, David, Flamm, Steven, Pauly, Mary Pat, Mukhopadhyay, Pabak, Griffel, Louis H., Brass, Clifford A.

“…This prospective, multicenter, community‐based and academic‐based, open‐label, investigator‐initiated, U.S. study evaluated efficacy and safety of pegylated…”
Get full text

235 SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With Hepatitis C Virus Genotype 1 by Jacobson, Ira M, Zeuzem, Stefan, Baykal, Tolga, Marinho, Rui T, Poordad, Fred, Bourliere, Marc, Sulkowski, Mark, Wedemeyer, Heiner, Tam, Edward, Desmond, Paul V, Jensen, Donald M, Di Bisceglie, Adrian M, Varunok, Peter, Hassanein, Tarek, Xiong, Junyuan, DaSilva-Tillmann, Barbara, Larsen, Lois, Podsadecki, Thomas

Get full text

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device by Varunok, Peter, Lawitz, Eric, Beavers, Kimberly L, Matusow, Gary, Leong, Ruby, Lambert, Nathalie, Bernaards, Coen, Solsky, Jonathan, Brennan, Barbara J, Wat, Cynthia, Bertasso, Anne

“…Peginterferon alfa-2a (40 kDa) is currently administered using a prefilled syringe. The peginterferon alfa-2a disposable autoinjector is a new…”
Get full text